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IκB kinase (IKK) complex, the master kinase for NF-κB activation, contains two kinase subunits, IKKα and IKKβ. In
addition to mediating NF-κB signaling by phosphorylating IκB proteins during inflammatory and immune
responses, the activation of the IKK complex also responds to various stimuli to regulate diverse functions
independently of NF-κB. Although these two kinases share structural and biochemical similarities, different
sub-cellular localization and phosphorylation targets between IKKα and IKKβ account for their distinct physiological
and pathological roles. While IKKβ is predominantly cytoplasmic, IKKα has been found to shuttle between the
cytoplasm and the nucleus. The nuclear-specific roles of IKKα have brought increasing complexity to its biological
function. This review highlights major advances in the studies of the nuclear functions of IKKα and the mechanisms
of IKKα nuclear translocation. Understanding the nuclear activity is essential for targeting IKKα for therapeutics.
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IκB kinase (IKK)/Nuclear factor kappa B (NF-κB) family
signaling mediates the expression of hundreds of genes
involved in inflammation, immune response, cell survival,
and cancer [1-4]. NF-κB proteins are part of a molecular
cascade that begins with signals outside the cell and cul-
minates in the nucleus by binding to DNA and activating
gene expression. The best-known form of NF-κB consists
of the DNA-binding subunit p50 and a transcription acti-
vator, p65 (also known as Rel A). In the absence of specific
extracellular signals, NF-κB inhibitors, such as IκB, p105,
and p100 proteins, tether to NF-κB in the cytoplasm to
prevent NF-κB-mediated gene transcription [1]. When
cells receive appropriate stimuli, such as tumor-necrosis
factor-α (TNF-α), a ternary IKK complex consisting of
IKKα, IKKβ and NEMO (IKKγ) induces IκB phosphoryl-
ation, leading to IκB ubiquitination and proteasomal
degradation that are required for liberation of NF-κB in
the nucleus where it binds to specific promoter elements
to activate gene expression [1,5].* Correspondence: whuang@mail.cmu.edu.tw; mhung@mdanderson.org
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distribution, and reproduction in any mediumAlthough IKKα and IKKβ share structural and bio-
chemical similarities, different phenotypes between IKKα
and IKKβ knockout mice imply distinct physiological
roles of the IKK isoforms [6]. IKKβ deficiency results in
embryonal death and shows the defective response to
inflammatory cytokines and liver cell apoptosis [7]. IKKα
knockout mice display the defective proliferation and
differentiation of kerationocyte and the abnormalities of
limb and skeleton, suggesting the requirement of the
IKKα subunit in morphogenesis [8]. Importantly, these
studies of gene knockout have shown that IKKα is dis-
pensable for IκB degradation although both IKKα and
IKKβ are critical for NF-κB-mediated gene expressions.
Instead of its role in phosphorylating IκBα in classic NF-
κB activation, IKKα homodimer has been shown to
mediate the processing of p100 precursor to p52 by the
noncanonical NF-κB pathway [5]. IKKα- and IKKβ-
deficient mouse embryo fibroblasts exhibit different
patterns of β-catenin cellular localization in which IKKβ
decreases β-catenin-dependent transcriptional activation
while IKKα increases β-catenin-dependent transcriptional
activity [9]. Differential requirements for IKKα and IKKβ
were also found in primary human osteoarthritic chondro-
cyte differentiation [10].
In addition to phosphorylating distinct substrates in
the cytoplasm [6,11], sub-cellular distribution of IKKα isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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these two related signaling kinases are functionally dif-
ferent. Many studies have indicated that IKKα can be
detected in both the cytoplasm and the nucleus whereas
IKKβ is detected predominantly in the cytoplasm [12-16].
The observation of nuclear/cytoplasm shuttling of IKKα
led to the discovery of the first nuclear role of IKKα in
phosphorylating histone H3, which results in NF-κB-
mediated gene expression [12,16]. These studies provided
an explanation of why IKKα is dispensable for IκBα
degradation but remains essential for NF-κB-dependent
transcription. Aside from nuclear regulation of NF-κB-
dependent gene transcription through chromatin modifi-
cation in response to pro-inflammatory stimuli, nuclear
IKKα also functions in apoptosis, cell cycle, and tumor
progression in colorectal [17,18], breast [19,20], pancreatic
[21], gastric [22], osteosarcoma [23], and prostate [24]
cancers. The current understandings of nuclear transloca-
tion and functions of IKKα are discussed below.
Nuclear IKKα regulates NF-κB-dependent gene
transcription and inflammation
Nuclear expression and functions of IKKα were first dis-
covered based on the observation of different patterns of
β-catenin activation in IKKα- and IKKβ-deficient mouse
embryonic fibroblast (MEF) cells by Lamberti et al. in
2001 [9]. Their study showed β-catenin-dependent tran-
scription was decreased by IKKβ but increased by IKKα
that is likely due to the differential abilities of IKKα and
IKKβ to bind to and phosphorylate β-catenin. Unlike theFigure 1 Nuclear IKKα-dependent molecular regulations of NF-κB-me
including proinflammatory cytokines, pathogens, and growth factors, IKKα
to phosphorylate histone H3 at Ser10, CBP at Ser1382/1386, and p65 at S53
NF-κB-dependent gene expression through phosphorylating SMRT at Ser24
enhanceosome to increase NF-κB-dependent gene expression. On the othe
mediated gene transcriptions by phosphorylating p65 at Ser536 and PIAS a
stimulation.predominantly cytoplasmic IKKβ, IKKα has been detected
in both the nucleus and the cytoplasm of MEF cells at
resting state [9,25]. The constitutive shuttling of IKKα
between cytoplasm and nucleus was further confirmed by
accumulation of IKKα in the nucleus of Hela cells in the
presence of a nuclear export blocking agent, leptomycin B
(LMB) [13]. Therefore, the protein binding and phosphor-
ylation of specific pools of β-catenin by IKKα in the
nucleus have been proposed to explain the contradictory
effect of the IKK isoforms on β-catenin-dependent tran-
scription [9]. However, the phosphorylation sites and
detailed mechanisms that account for the differential regu-
lation of β-catenin by IKK isoforms remain to be explored.
IKK complex is activated in response to various stimuli
involving inflammation, apoptosis, immune response,
and cancer. These physiological and pathological stimuli
have been reported to enhance the nuclear levels of
IKKα (Figure 1). TNF-α, a critical pro-inflammatory
cytokine, was the first stimulant for IKKα nuclear trans-
location identified [12,16]. Other inducers of alterative
NF-κB pathway, including lymphotoxin β and CD40,
also elicit nuclear IKKα signaling [15]. In addition to
TNF-α, Helicobacter pylori (HP) can also trigger nuclear
translocation of IKKα via its virulence factor CagA protein
to induce cytokine production for appropriate inflamma-
tory responses [22]. Similarly, overexpression of Kaposi’s
sarcoma-associated herpesvirus (KSHV)-encoded viral
FLICE inhibitory protein K13 [26] and hepatitis B virus-
encoded X (HBx) protein [14] also induce IKKα nuclear
translocation to regulate NF-κB activity. The requirementdiated gene transcription. In response to a variety of stimuli,
translocates into the nucleus and bind to DNA in association with CBP
6. Nuclear IKKα also removes repressive HDAC3/SMRT complex from
10. These events facilitate the formation of transcriptional
r hand, nuclear IKKα also contributes to the termination of NF-κB-
t Ser90 to facilitate the turnover of p65 in response to TNF-α or LPS
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of IKKα for NF-κB-dependent gene regulation in a TAK1-
dependent manner in TLR4-activated antigen-presenting
cells [27] and activated neutrophils [28,29] further support
that nuclear IKKα functions as a common and important
regulator for NF-κB activity in response to various im-
mune and inflammatory stimuli (Figure 1).
As illustrated in Figure 1, TNF-α-induced nuclear IKKα
mediates NF-κB-dependent gene transcription, regardless
of IκBα degradation, by enhancing transactivation [25]
and DNA binding [30] of p65 as well as chromatin regula-
tion through its interaction CREB-binding protein (CBP),
a histone acetyltransferase [15,16]. Phosphorylation of
serine residues within the transactivation domains (TA1
and TA2) of p65 is responsible for transcriptional activa-
tion of the NF-κB target genes [31]. By employing the
Gal4 DNA binding domain fused to the p65 transactiva-
tion portion in a heterologous luciferase reporter assay,
nuclear IKKα was shown to transduce NF-κB-inducing
kinase (NIK)-dependent p65 TA1 transcriptional activity,
suggesting that IKKα phosphorylates the TA1 domain of
p65 in the nucleus [25]. In addition, using the IKKα
mutant lacking an intact nuclear localization sequence
(NLS), p65 chromatin immunoprecipitation assays further
revealed that nuclear IKKα plays a role in binding activity
of NF-κB/p65 to some but not all NF-κB-target promoters
by removing histone deacetylase 3 (HDAC3), a negative
regulator of NF-κB-dependent transcription, from these
promoters [30]. Even though several earlier studies have
implicated the function of IKKα in chromatin, the role of
nuclear IKKα as a chromatin modifier was not reported
until later by Baldwin’s and Gaynor’s group [12,16]. They
showed that IKKα functions as a chromatin kinase in the
nucleus and targets histone H3 at Ser10 for activation of
NF-κB-directed gene expression (Figure 1). The nuclear
import, chromatin association, histone phosphorylation of
IKKα relies on its kinase activation by the upstream NIK
kinase in response to both TNF-α and endotoxin lipopoly-
sarccharide (LPS) [32]. However, the correlation between
chromatin-bound IKKα and histone H3 phosphorylation
on NF-κB-target genes was not found in human prostate
carcinoma DU145 cells [18], indicating that cell type- and
target gene-specificity exists in IKKα-dependent histone
phosphorylation.
Gaynor’s group further showed that nuclear IKKα
interacts with the transactivation domain of CBP. The
IKKα/CBP complex in conjunction with p65 is recruited
to the NF-κB responsive promoters to mediate cytokine-
induced phosphorylation and subsequent acetylation of
specific residues in histone H3 [16]. These findings
suggested that IKKα not only targets on NF-κB but also
functions as a key epigenetic regulator to initiate se-
quential chromatin modifications. Our studies also
demonstrated that nuclear IKKα binds directly to CBPand phosphorylates its HAT domain at Ser1382 and
Ser1386 to enhance the enzymatic activity of CBP on
histone acetylation [15] (Figure 1). CBP and its homolog,
p300, are transcriptional coactivators that function in
the communication between transcription factors and
the transcriptional machinery [33]. Since the availability
of these coactivators is limited due to their essentiality
for large number of transcription factors, competition
between different transcription factors for CBP or p300
has been proposed to play a role in the coordination of
gene expression and the appropriate execution of many
biological processes [34]. Our study further demon-
strated that the IKKα-dependent CBP phosphorylation
enhances NF-κB-mediated gene expression and sup-
presses p53-mediated gene expression by switching the
binding preference of CBP from p53 to NF-κB, thereby
promoting cell growth [15]. Similar to IKKα, IKKγ/
NEMO has also been shown to shuttle between the
cytoplasm and the nucleus and to compete with p65 and
IKKα for binding to the N-terminus of CBP. Even
though IKKγ/NEMO is essential for the kinase activity
of IKK complex in the cytoplasm, it seems to act as a
negative regulator of nuclear IKKα and inhibit CBP-
dependent transcriptional activation in the nucleus [35].
CBP and p300 mediate acetylation of histones as well
as many transcription factors, including p65, for their
transcriptional potential [33]. Acetylation of p65 is crit-
ical for its DNA binding and transactivation activity
[36,37]. In contrast, deacetylation of p65 by HDACs, in-
cluding HDAC1, HDAC2, HDAC3, and SIRT1, has been
reported to repress its transcriptional activity [38,39].
The enzymatic activities of HDACs are regulated by their
ability to associate with co-repressor proteins, such as
SMRT and NCoR [40]. Chromatin-associated HDAC3/
SMRT complex tethered by p50 homodimers on NF-κB-
target cIAP and IL-8 promoters of unstimulated cells is
responsible for the basal suppression of NF-κB-regulated
gene transcriptions [18]. In addition to enhancing histone
acetylation by targeting CBP, IKKα was also found to re-
lieve the suppression of NF-κB-mediated transcription by
removing the HDAC3/SMRT repressor complex from tar-
get promoters [18,30,41]. Chromatin immunoprecipitation
analysis demonstrated that upon attachment to laminin,
the induction of chromatin-associated IKKα protein and
acetylated histone is accompanied by a decrease in
chromatin-bound HDAC3/SMRT complex. Direct phos-
phorylation of SMRT at Ser2410 by IKKα on chromatin
also stimulates nuclear export and proteasomal degrad-
ation of the HDAC3/SMRT complex by recruiting TBL1/
TBLR1, Ubc5, and 14-13-3ε proteins [18]. The removal of
HDAC3/SMRT by IKKα allows the active p50-RelA/p65
heterodimer of NF-κB to bind and potentiate transcription
(Figure 1). Although the SMRT corepressor returns to the
chromatin-bound NF-κB complex almost immediately
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promoter, IKKα remains associated with the chromatin
and phosphorylates both p65 at Ser536 and SMRT at
Ser2410 to prevent the recruitment and chromatin associ-
ation of HDAC3 at the NF-κB-regulated promoter.
Displacement of HDAC3 from active NF-κB allows p300
to load and subsequently acetylate p65 at Lys310, which is
required for full NF-κB transcription [41]. Thus, IKKα-
mediated derepression of SMRT is an initial step critical
for NF-κB transcription and survival in response to
laminin attachment. Interestingly, cigarette smoke extract
(CSE) was recently reported to induce the translocation of
IKKα from cytoplasm to nucleus in mouse lung tissue in a
dose-dependent manner. CSE-activated nuclear IKKα
mediates the pro-inflammatory gene transcription through
phospho-acetylation of RelA/p65 and histone H3 [42],
suggesting nuclear IKKα-targeted histone H3, SMRT, and
CBP/p300 play a role in CSE-induced NF-κB activation.
In contrast to activating NF-κB in response to proin-
flammatory stimuli, IKKα kinase activity has been reported
to be required for the termination of NF-κB activation
[43]. In response to the systemic challenge with the
Gram-positive human pathogen group B Streptococcus
(GBS), transgenic mice expressing the inactivatable variant
of IKKα (AA) showed higher bacterial clearance but acce-
lerated mortality compared with the wild-type mice. The
exacerbated inflammatory phenotype was believed to be
associated with this paradoxical result. Indeed, after
administration of the Escherichia coli-derived LPS,
transcripts of several pro-inflammatory and antiapoptotic
NF-κB-target genes were higher in IKKαAA/AA mice than
in the littermate controls, indicating a role of IKKα in
terminating the activation of classical NF-κB pathway in
response to LPS-induced Toll-like receptor (TLR) signal-
ing. It was then demonstrated that IKKα activity is
required to accelerate the removal of RelA/p65 and c-Rel
from pro-inflammatory gene promoters and the turnover
of these NF-κB subunits by specifically phosphorylating
p65 within its transactivation domain at Ser536. These
events terminate LPS-induced NF-κB activation, leading
to the negative regulation of macrophage activation and
inflammation [43] (Figure 1). While much attention has
focused on pro-inflammatory signaling, this study
explored an opposing but complimentary role of IKKα in
resolving inflammation. Since IKKα also showed nuclear
function in histone phosphorylation in LPS-treated
macrophage [32], this raises the possibility that LPS-
activated IKKα also phosphorylates p65 at Ser536 in the
nucleus to terminate the transcriptional activity of NF-κB.
However, this hypothesis seems contradictory to the previ-
ous finding that TNF-α-induced NIK/IKKα complex
phosphorylates p65 at Ser536 in the nucleus to enhance
NF-κB activity [25]. These findings suggest that the tran-
scriptional activity of NF-κB is not determined merely byp65 Ser536 phosphorylation and other regulatory factors
are required. The work by Liu et al. further demonstrated
that protein inhibitor of activated STAT1 (PIAS1), a gene-
specific transcriptional repressor with SUMO E3 ligase
activity, is involved in the IKKα-mediated negative regula-
tion of NF-κB and inflammation restriction [44]. In
response to various inflammatory stimuli, including TNF-
α and LPS, PIAS is rapidly phosphorylated at Ser90, and
this phosphorylation is mediated by IKKα and required
for its association with chromatin and enzymatic activity
to repress promoter-binding and transcriptional activities
of NF-κB [44]. It would be interesting to further address
the relationship between p65 Ser536 phosphorylation and
PIAS Ser90 phosphorylation in the IKKα-mediated nega-
tive regulation of NF-κB activity (Figure 1).
Nuclear functions of IKKα in NF-κB-independent gene
transcription regulation
Nuclear IKKα-mediated histone H3 phosphorylation is
involved in c-fos upregulation in a NF-κB-independent
manner in response to EGF [45] and UV [46] stimula-
tion (Figure 2). Dong et al. demonstrated that Ser32
phosphorylation, which is required for c-Fos protein sta-
bility and promoter recruitment of c-Fos, requires the
kinase activity of nuclear IKKα [46], indicating that the
chromatin regulation by nuclear IKKα is not limited to
NF-κB-targeted genes but also affects gene transcrip-
tions regulated through targeting various transcription
factors or cofactors (Figure 2). For example, IKKα-
mediated suppression of SMRT is required not only for
NF-κB activation [18] but also Notch-dependent tran-
scription [17], implying that nuclear IKKα may function
as a common epigenetic regulator for gene transcription.
Our recent study further indicated that nuclear IKKα
may also derepress Notch-dependent transcription by
diminishing the gene expression of NUMB [47], which
targets Notch1 for lysosomal degradation through
protein-protein interaction [48]. We identified forkhead
box protein A2 (FOXA2) as the transcription factor for
NUMB gene transcription and demonstrated that IKKα
reduces the transcriptional activity of FOXA2 via bind-
ing to and phosphorylating it at Ser107 and Ser111 [47].
Therefore, nuclear IKKα may also enhance Notch-
dependent gene transcription by suppressing FOXA2/
NUMB signaling pathway (Figure 2). In addition to Notch,
IKKα but not IKKβ was found to be involved in estrogen
receptor (ER)-mediated gene transcription by binding to
the estrogen-responsive elements (EREs)-containing pro-
moters and phosphorylating histone H3, ERα, or coac-
tivators such as AIB1/SRC-3. Coordinated promoter
recruitment of ERs and specific coactivators, such as SRC-
1, AIB1/SRC-3, GRIP1, CBP/p300, PCAF, CARM1, and
PRMT1, is required for estrogen-regulated transcriptional
activation. By forming a transcriptional complex with ERα
Figure 2 The roles of nuclear IKKα in the regulation of NF-κB-independent gene transcription. Nuclear IKKα enhances Notch-dependent
gene transcriptional by phosphorylating and removing co-repressor SMRT from target gene promoters. IKKα also contributes to Notch
transcriptional activity through phosphorylating and inactivating FOXA2, which subsequently leads to NUMB suppression. By direct target on
transcription factors, nuclear IKKα also increases AP-1, ERα, and E2F-mediated gene transcription. Phosphorylation of SRC3 at Ser857 by nuclear
IKKα also contributes to ERα transcriptional activity.
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ation on the promoters of several estrogen-responsive
genes. In addition, nuclear IKKα also enhances the activ-
ities of ERα and AIB1/SRC-3 through phosphorylation of
their Ser118 and Ser857 respectively (Figure 2), leading to
the increase in cyclin D1 and Myc expression and
estrogen-mediated breast cancer cell growth [19].
Since IKKα-activated SRC3 is also required for tran-
scriptional activity of NF-κB [49], SRC-3 coactivator,
in addition to histone H3 and SMRT, may also be
another target of nuclear IKKα to increase general
gene transcriptions.
In response to estrogen stimulation, IKKα also regulates
cell cycle progression through modulating E2F1-depedent
transcription [20]. The Rb/E2F pathway controls G1/S
phase transition by activating expression of genes required
for DNA replication. Silencing of IKKα but not IKKβ sig-
nificantly reduced estrogen-induced cell cycle progression
and transcription of the E2F1 gene as well as other E2F1-
responsive genes, including thymidine kinase 1, proliferat-
ing cell nuclear antigen, cyclin E, and cdc25A, indicating
that IKKα plays a critical role in regulating E2F-dependent
gene transcription. Through association with E2F1, IKKα
is recruited to E2F-1 responsive promoters and potentiates
the ability of p300/CBP-associated factor to acetylate E2F1
for transcriptional activation in response to estrogen treat-
ment (Figure 2). These findings suggest that nuclear IKKαinfluences estrogen-mediated cell cycle progression by
modulating E2F1 at both the transcriptional and posttran-
scriptional levels [20]. Taken together, IKKα appears to
modulate various epigenetic signaling pathways to regu-
late specific sets of genes.
Regulation of apoptosis by nuclear IKKα
NF-κB is activated to control apoptosis upon exposure
to various cytotoxic stimuli, including reactive oxygen
species (ROS). Recent evidence suggests a negative regu-
latory role of activated NF-κB in ROS-elicited JNK
signaling to antagonize apoptosis [50]. Interestingly, the
Src-dependent Tyr42 phosphorylation but not IKK-
mediated Ser32/36 phosphorylation of IκBα contributes
to ROS-induced NF-κB activation in a proteolysis-
independent mechanism [51,52]. Although hydrogen
peroxide stimulation has been shown to induce IKKα
activity and thus its nuclear translocation, it had no
effect on NF-κB activation [53], suggesting that IKKα is
not involved in the ROS-induced NF-κB activation. In
contrast to the pro-survival role of NF-κB, nuclear IKKα
plays an opposite function in ROS-mediated apoptosis
through modulating p53 transcriptional activity (Figure 3).
In the nucleus, IKKα enhances p53-mediated GADD45
and BAD gene expressions by phosphorylating p53 at
Ser20 [53] and stabilizing p53 protein levels [54], leading
to the induction of apoptosis in response to ROS exposure.
Figure 3 Nuclear IKKα targets p53 and p73 to mediate apoptosis. In response to DNA damage induced by ROS and cisplatin, nuclear IKKα
stabilizes p53 and p73 protein level respectively to promote apoptosis.
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p73 function against NF-κB in deciding cell fate. Treat-
ment with cisplatin induces IKKα nuclear translocation in
human osteosarcoma-derived U2OS cells and hepatocellu-
lar carcinoma HepG2 cells in an ATM-dependent manner
[23,55]. As shown in Figure 3, nuclear IKKα also stabilizes
p73 protein through physical interaction in response to
cisplatin [23]. Although the exact residue of p73 phos-
phorylated by IKKα has not yet been identified, a study
showed that nuclear IKKα phosphorylates p73 within its
N-terminal region, which may protect p73 from ubiquiti-
nation and proteasomal degradation [23]. These findings
suggest an indispensable role of IKKα in cisplatin sensitiv-
ity. Different from ROS-induced nuclear IKKα on p53
stability in ROS-treated human MOLT-4 and HL-60
leukemia cells, cisplatin-activated IKKα nuclear transloca-
tion did not lead to p53 stabilization in HepG2 cells
[53,54], suggesting that IKKα-dependent protein sta-
bilization is cell type- and stimulus-specific.
Nuclear IKKα is essential for cell cycle arrest and
differentiation of keratinocyte in the epidermis and the
morphogenesis of skeletal and craniofacial morphogenesis
Unlike its well-established role in anti-apoptosis, the in-
volvement of NF-κB in regulating cell cycle progression
remains unclear. NF-κB activation is required for cell
cycling in fibroblast [56], regenerating liver cells [57],
breast cancer cells [58], and HeLa cells whereas NF-κB
inhibition impairs cell cycle progression and retardation
of G1/S transition [59]. During cell cycle, D-type cyclins
(cyclin D1, D2, and D3) are critical for G1 to S phase
progression. By phosphorylating the retinoblastoma
tumor suppressor protein (pRb), cyclin D with its part-
ner cyclin-dependent kinases (CDKs), releases the E2Ffamily of transcription factors to activate the expression
of cyclin E and several other genes required for the cell
cycle progression [60,61]. The direct binding of NF-κB
on the promoter region of cyclin D1 gene and the pro-
nounced reduction of cyclin D1 expression by NF-κB in-
hibition provide additional evidence for the involvement
of cyclin D1 transcription in NF-κB-mediated cell cycle
progression [62-64]. However, several studies showed
contradictory results in which NF-κB activation by over-
expression of p65 or c-Rel causes cell-cycle arrest and
induces cells to commit to terminal differentiation
[65,66]. For instance, the G1-arrest by p65 occurs in
pro-B but not in mature B cells [66], suggesting that this
event depends on cell developmental stage. Interestingly,
mouse with IKKα gene inactivation also had an unex-
pected excessive proliferation of the skin basal layer due
to the absence of epidermal differentiation [67,68]. The
specific roles of NF-κB in IKKα-mediated cell cycle ar-
rest and subsequent differentiation in keratinocyte was
initially proposed based on the observation that NF-κB
activation is not detectable in keratinocytes from IKKα-
null mouse skin [69]. However, a subsequent study
pointed out that IKKα controls epidermal keratinocyte
differentiation independently of NF-κB activation but
regulates cyclin D1 protein stability in which cyclin D1
is overexpressed and predominantly localized in the nu-
cleus of IKKα−/− MEF cells compared with parental
MEF cells [70]. In vitro binding and kinase assays
showed that IKKα directly binds cyclin D1 and phos-
phorylates it at Thr286. The cytoplasmic expression and
increased degradation of cyclin D1 by reconstitution of
IKKα in knockout cells further suggest that this phos-
phorylation by IKKα is required for nuclear export and
turnover of cyclin D1 [71]. The predominantly nuclear
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cyclin D1 in the nucleus and regulates its nuclear export.
The potential nuclear function of IKKα in facilitating
cyclin D1 protein degradation but not in NF-κB activa-
tion may be attributed to IKKα-mediated cell cycle ar-
rest and differentiation of keratinocytes (Figure 4).
Indeed, keratinocyte differentiation is associated with
increased nuclear distribution of IKKα. Inactivation of
the NLS by site-directed mutagenesis prevents IKKα
from entering the nucleus without affecting its kinase
activity and blocks the IKKα-induced differentiation of
primary cultured IKKα−/− keratinocyte, supporting an
essential role of nuclear IKKα in the keratinocyte differ-
entiation [8]. Likewise, Marinari et al. also found that
nuclear IKKα can act as a tumor suppressor in stratified
epithelia [72]. After stimulation with TGFβ, IKKα accu-
mulates in the nucleus of keratinocytes and occupies the
promoter of genes responsive to TGFβ-SMAD signaling
to mediate TGFβ-induced Ovol1 and Mad1 upregulation
and Myc downregulation (Figure 4). Such activity of nu-
clear IKKα is important for the anti-proliferative TGFβ
pathway. In contrast, the expression and nuclear loca-
lization of IKKα are gradually reduced during malignant
progression of squamous cell carcinoma (SCC) and ac-
quisition of an invasive phenotype [72], which supports
the tumor suppressive role of nuclear IKKα. However,
the function of TGFβ-induced nuclear IKKα seems to
counter its metastatic role in breast cancer cells [73]
(please see below), suggesting a keratinocyte-specific role
of nuclear IKKα in suppressing cell proliferation.
Besides the failure of epidermal differentiation, IKKα-
deficient mice also exhibit abnormalities in skeletal andFigure 4 Regulations of cell cycle progression by nuclear IKKα. In the
increasing Smad transcriptional activity, facilitating cyclin D1 proteasomal d
M phase progression by increasing kinase activity of Aurora A and by de-re
histone methylation on the promoter.craniofacial morphogenesis [70,74], which is not observed
in mice with systemic inhibition of NF-κB [75]. The
results from these studies further support the dispensable
role of NF-κB in nuclear IKKα-mediated keratinocyte dif-
ferentiation. By introducing an epidermal-specific IKKα
transgene into IKKα-deficient mice, most of these
morphological abnormalities were completely rescued,
suggesting that nuclear IKKα-dependent epidermal differ-
entiation control skeletal and craniofacial morphogenesis
[8]. In addition to targeting cyclin D1 protein degradation,
another potential mechanism by which nuclear IKKα
affects keratinocyte differentiation and craniofacial and
skeletal morphogenesis is through repression of the fibro-
blast growth factor (FGF) family members [8], which bind
to FGF receptor (FGFR) to antagonize bone morphogenic
protein (BMP) signaling [76]. Since reintroduction of a
catalytically inactive form of IKKα in IKKα−/− mice is still
able to rescue epidermal differentiation and skeletal mor-
phogenesis, the developmental functions of IKKα have
been proposed to be independent of its protein kinase
activity [76]. Therefore, nuclear IKKα may also contribute
to the suppression of FGF transcription through a kinase-
independent manner, hence excluding its involvement in
phosphorylating histone H3 (Figure 4). Exploration of the
kinase-independent roles of nuclear IKKα awaits further
studies.
In addition to G1/S transition, IKKα also has a role in
regulating the M phase of cell cycle as shown in Figure 4.
Progression through the M phase of cell cycle is
dependent on several mitotic kinases, including those of
the Aurora families [77]. Aurora A localizes to the
centrosome and functions in centrosome maturationnucleus, IKKα is involved in cell cycle arrest at G1/S transition by
egradation, and FGF gene expression. Nuclear IKKα also promotes G2/
pressing 14-3-3 σ gene expression through preventing DNA and
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A by siRNA increased the percentage of mitotic cells
with high levels of Plk1 and cyclin B1 [78]. In a similar
pattern to Aurora A siRNA knockdown, Prajapati et al.
showed that silencing of IKKα but not IKKβ by siRNA
also increased the number of HeLa cells at the G2/M
phase and the levels of Plk1 and cyclin B1 [79]. These
results further revealed that IKKα is associated with
Aurora A in the centrosome and directly phosphorylates
Aurora A at Thr288 [79], suggesting a nuclear function
of IKKα in regulating the M phase of the cell cycle
through Aurora A phosphorylation. In addition to tar-
geting Aurora A, chromatin-bound IKKα also maintains
the progression of G2/M phase during the cell cycle by
preventing the silencing of 14-3-3σ, a check point
protein for G2/M phase transition [80]. In IKKα-defi-
cient keratinocytes that showed cell cycle arrest at the
G2/M phase, the SUV39h1 histone trimethyltransfer-
ase and the Dnmt3a DNA methyltransferase were
found to associate and methylate histone H3 lysine-9
(K9) and 14-3-3σ locus DNA, respectively, which then
silenced 14-3-3σ expression. Reintroduction of wild-
type (WT) IKKα, but not its chromatin-unbound
mutants bearing defects within the leucine zipper do-
main and helix-loop-helix motif, restored the 14-3-3σ
expression by preventing the association of SUV39h1
and Dnmt3a with the 14-3-3σ locus, indicating that
chromatin-associated IKKα prevents 14-3-3σ from
hypermethylation (Figure 4). Interestingly, the kinase
activity of IKKα is dispensable for blocking 14-3-3σ
hypermethylation [80], suggesting that nuclear IKKα may
protect 14-3-3σ from hypermethylation through an unex-
plored kinase-independent mechanism.Figure 5 Nuclear IKKα and tumor progression. Nuclear IKKα promotes t
transcriptions and suppressing FOXA2-mediated gene expression. By prom
gene expression, nuclear IKKα contributes to cancer metastasis.Nuclear function of IKKα in tumorigenesis and metastasis
Constitutive activation of NF-κB has been found in
many types of tumor cells. Most of these studies report
an increased IKK activity that results in phosphorylation
of IκBα; however, some have found little or no changes
in the subcellular localization of p65 in some of the
tumor cells. For instance, Fernández-Majada et al.
reported that the increased IKK activity in colorectal
cancer (CRC) cell lines and primary CRC is concomitant
with undetectable levels of nuclear p65 and p52, which
is consistent with the absence of p65 and p52 on differ-
ent promoters of NFκB-target genes detected by ChIP
analysis. These results indicate that NFκB activation may
not be the main consequence of IKK activity in colorec-
tal tumors, reflecting the substrate specificity of different
IKK complexes. By immunohistochemistry staining and
subcellular fractionation followed by Western blot ana-
lysis, they also showed that IKKα is present in the nu-
cleus of most primary colorectal tumor tissues and CRC
cell lines but not in HS27 or HEK-293 control cells. The
increase in nuclear IKK activity in colorectal tumors is
significantly correlated with SMRT phosphorylation at
Ser2410 and its cytoplasmic translocation (Figure 5). At
the chromatin level, the association of IKKα to specific
Notch target promoters results in the release of
chromatin-bound SMRT and thus activating hes1, hes5,
or herp2/hrt1 transcription, which promotes cell prolif-
eration by repressing transcription of the cyclin-
dependent kinase inhibitor p27Kip1 [17]. In addition, we
reported that enhancement of Notch transactivation by
IKKα through inhibition of FOXA2/NUMB signaling is
also likely to contribute to inflammation-mediated liver
cancer progression [47]. Our other study also indicatedumor growth by enhancing NF-κB- and Notch-dependent gene
oting Smad and STAT3 transcriptional activity and suppressing maspin
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cancers, including lung, liver, pancreatic, and ovarian can-
cers, can phosphorylate and direct CBP to bind preferen-
tially to NF-κB but not p53, thereby favoring proliferation
and survival over p53-dependent apoptosis [15].
The epithelial to mesenchymal transition (EMT) is a
crucial step in tumor progression in many tumor types.
Independently of NF-κB activation, nuclear IKKα has been
implicated in EMT by enhancing gene expression of
SNAIL and SLUG transcription factors to downregulate
expression of the adherens junction protein E-cadherin.
As shown in Figure 5, IKKα enters the nucleus and regu-
lates gene expression of SNAIL and SLUG by interacting
with SMAD3 and controlling SMAD complex formation
on the promoters of these two transcription factors in
response to TGFβ activation, leading to metastasis of
breast cancer cells [73]. Tumor-infiltrating immune cells
expressing lymphotoxin-β [81] and RANKL [24] have also
been found to induce activation and nuclear localization
of IKKα in prostatic epithelial tumor cells (Figure 5). After
castration, activated STAT3 has been reported to promote
the transcriptional activity of unliganded androgen recep-
tor in prostate cancer cells [82]. Lymphotoxin β-induced
nuclear IKKα, in conjunction with STAT3, contributes to
the emergence of castration resistance and enhances
hormone-free survival and metastasis of prostate cancer
by an NF-κB-independent, cell autonomous mechanism
[81]. By targeting histone H3 Ser10 on the promoter of
maspin, nuclear IKKα was also proposed to mediate the
repression of maspin, a critical suppressor of metastasis,
through an unidentified mechanism, which then commits
malignant prostatic epithelial cells to a metastatic fate
[24]. Similarly, we found that overexpression of HBx
reduced maspin expression in Hep3B cells, and expression
of wild-type IKKα but not its NLS mutant suppressed
maspin expression in Hep3B cells, indicating that nuclear
IKKα likely plays a role in HBx-mediated cell migration
and invasion via suppressing maspin expression [14].
Although nuclear IKKα has been proposed to suppress
maspin expression via histone H3 Ser10 phosphorylation
[24] (Figure 5), it is still unclear how this histone phos-
phorylation reduces the promoter activity of maspin.
Taken together, these findings indicate that a specific set
of genes regulated by nuclear IKKα plays a critical role in
tumorigenesis and metastasis. The detailed molecular
mechanisms await further investigations.
Potential mechanisms of IKKα nuclear translocation
Exploration of various nuclear IKKα functions raised a
fundamental question of how IKKα travels from the
cytoplasm to the nucleus. It is believed that, for a major-
ity of proteins, NLS-bearing molecules are transported
into the nucleus by forming a complex with importin α/β
[83] or importin β alone [84]. A lysine-rich motif, Lys235,Lys236, and Lys237 within the kinase domain of IKKα has
been shown to contain the NLS. Mutation of these resi-
dues attenuated the spontaneous nuclear import of IKKα
but did not interfere with its kinase activity or binding to
IKKγ [8]. We also characterized the signaling peptide for
IKKα nucleo-cytoplasmic shuttling in response to HBx
overexpression and found that in addition to these three
lysines, two additional lysines (233 and 240) are also
required for the nuclear translocation of IKKα [14]. The
energy for the importin-based nuclear transport is
provided by the small Ras family GTPase, Ran [85]. A
dominant negative mutant of Ran has been reported to in-
hibit IKKα nuclear translocation [25], suggesting that the
nuclear import of IKKα requires importins. However, the
specific molecules that are involved in NLS-mediated
IKKα nuclear translocation remain to be investigated.
Likewise, nuclear export signals (NES), which are
recognized by a soluble export receptor (also known as
Exportin 1 or CRM1), mediate nuclear export [86]. A
study in 2002 by Birbach et al. showed that presence
and incubation of LMB, an inhibitor of CRM1, enhanced
the levels of IKKα in the nucleus [13]. This raises the
possibility that IKKα can shuttle out of the nucleus
through the CRM1 pathway and contains an NES to
allow for the recognition and binding of CRM1 receptor.
Based on the consensus NES sequence, which typically
has a leucine-rich consensus sequence in the form of
LX1-3LX2-3LXL (L=leucine and X=any amino acid) [86],
there are two putative NESs (Leu601 ~ Leu612 and
Leu714~Leu724) located at the C-terminus of IKKα.
Leucine or isoleucine substitution within the motif con-
taining residues 714–724 enhanced nuclear accumula-
tion of IKKα, thereby supporting the presence of an NES
for IKKα nuclear export [14].
Since IKKα can enter the nucleus in response to diverse
stimuli, including TNF-α [12,16], Helicobacter pylori [13],
estrogen [20], EGF [45], and cisplatin [55], it is likely that
signaling pathways, in addition to NLS and NES, are also
critical for regulating IKKα nucleo-cytoplasmic shuttling
(Figure 6). A kinase-dead mutant of IKKα (IKKα-K44M)
has been shown to have lower nuclear accumulation than
the wild type form, indicating that kinase activation is
required for IKKα to translocate into the nucleus [13].
Activation of IKK complex usually involves trans-
autophosphorylation by the catalytic domains of IKKα
and IKKβ. However, knockdown of IKKβ by siRNA had
no effect on H. pylori-induced IKKα nuclear translocation
[22]. This suggests that IKKα can bypass the classic IKK
complex activation pathway to enter the nucleus. As IKKβ
does not exist in the nucleus, the distinct mechanisms by
which the kinases are regulated may have a role in
controlling the nuclear translocation of IKKα. Indeed,
Akt, a mitogen-activated survival factor, has been shown
to increase the activity of IKKα but not IKKβ by
Figure 6 Molecular mechanisms of IKKα nuclear transportation. Ran GTPase activity is required for the nuclear transport of IKKα through
interacting with importin-α. In response to HBx overexpression and cisplatin treatment, phosphorylations of IKKα at Thr23 and Ser473 by Akt and
ATM respectively promote its nuclear translocation. The ubiquitination of IKKα is essential for the Akt-regulated IKKα nuclear import. Under
exposure to ROS, activated PKCδ also enhances the nuclear accumulation of IKKα.
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Intriguingly, the signals that stimulate IKKα nuclear im-
port, including HBx, EGF, HER2, and TNF-α, also com-
monly induce Akt activation. Akt-enhanced nuclear
expression of IKKα is further augmented by overexpres-
sion of ubiquitin, suggesting that ubiquitination plays a
role in Akt-regulated IKKα nuclear transportation [14].
Further investigations are necessary to identify the E3
ligase and the ubiquitination sites of IKKα.
In response to cisplatin-induced DNA damage, ATM
has been shown to activate and phosphorylate IKKα at
Ser473 in an in vitro kinase assay. Treatment with ATM
inhibitors blocked the nuclear IKKα accumulation by
cisplatin, suggesting that ATM plays a role in the nuclear
translocation of IKKα. In addition, the active form of
ATM was shown to colocalize with IKKα in the nucleus
to mediate cisplatin-induced p73 protein stabilization
and apoptosis [55]. These findings suggest that Ser473
phosphorylation by ATM may be a critical posttransla-
tional modification for IKKα nuclear import and func-
tions in response to cisplatin treatment. Similarly, in
response to ROS exposure, PKCδ has also been demon-
strated to increase the kinase activity and nuclear trans-
location of IKKα through protein-protein interaction
(Figure 6). PKC-activated nuclear IKKα promotes the
stability of p53 protein and mediates ROS-induced
apoptosis [53]. However, the phosphorylation site
mediated by ROS-activated PKC remains unclear. It
would be of interest to further address whether phos-
phorylation of IKKα by Akt, ATM, or PKCδ at different
residues affects its substrate preference in the nucleus.Conclusion
Since the first observation of nuclear localization of
IKKα more than a decade ago, the field has gained
tremendous insight into the distinct regulation and func-
tions of nuclear IKKα. Other than IκB protein in the
cytoplasm, these studies added histone and transcrip-
tional co-factors as nuclear targets of IKKα for activation
of NF-κB-dependent transcription. By targeting a grow-
ing list of substrates in the nucleus, IKKα has also been
implicated in a variety of biological functions, including
apoptosis, tumor suppression, immune functions, cell
proliferation, and chromatin remodeling in an NF-κB-
independent manner. Dysregulation of nuclear IKKα has
been further linked to diabetes [88]. Contextual condi-
tioned fear memory may also transduce IKKα to the nu-
cleus of hippocampus for transcriptional regulation after
memory recall [89]. These findings uncovered functional
diversity of nuclear IKKα and other probable roles
worthy of further exploration. For example, the involve-
ment of nuclear IKKα in the termination of NF-κB sig-
naling is an attractive yet under-developed area. The
exploration of the nuclear role of IKKα in terminating
NF-κB activity could lead us to understand how inflam-
mation is resolved. The kinase-independent function of
nuclear IKKα, which has been shown to control FGF
suppression during epidermal differentiation and skeletal
morphogenesis, is also another interesting area requiring
further investigations. Addressing the kinase-independent
functions of IKKα will likely provide more comprehensive
explanation for the distinct roles between IKKα and its
homologue, IKKβ.
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http://www.jbiomedsci.com/content/20/1/3In the past decade, there has been increased interest in
the therapeutic disruption of the IKK/NF-κB pathway by
using various approaches ranging from genetic manipu-
lation to the development of pharmacologic inhibitors of
IKK for inflammatory and autoimmune diseases [90,91].
Preclinical studies have also suggested IKKα/β as a
therapeutic target for inhibition of NF-κB activity in
various types of cancer [91], but translation of this
mechanistic knowledge to clinically relevant therapeutic
is much more difficult than researchers’ expectation. In-
stead, much of the effort toward the development of
IKKβ and other NF-κB inhibitors has come from the
pharmaceutical industry [90]. The limitation of clinical
development of IKKβ inhibitors is probably due to the
detrimental effects of excessive and prolonged NF-κB
inhibition by IKKβ inhibition on innate immunity [92].
Although potent IKKα-specific inhibitors have not yet
been described, the dispensability of IKKα in classic NF-
κB activation and the unique roles of nuclear IKKα in
modulating NF-κB-independent pathological activity,
which are important for tumor progression, indicate that
the chromatin-associated IKKα might be a promising
target for therapeutic intervention in cancer. An ideal
inhibitor designed to abrogate nuclear IKKα functions
involved in a particular disease is therefore anticipated
to minimize systemic toxicity and avoid general suppres-
sion of innate immunity, and may provide a more spe-
cific and safer therapeutic efficacy for cancer therapy.
Abbreviations
BMP: Bone morphogenic protein; CBP: CREB-binding protein; CDK: Cyclin-
dependent kinase; CRC: Colorectal cancer; CSC: Squamous cell carcinoma;
CSE: Cigarette smoke extract; EMT: Epithelial to mesenchymal transition;
ER: Estrogen receptor; ERE: Estrogen-responsive element; FGF: Fibroblast
growth factor; GBS: Gram-positive human pathogen group B Streptococcus;
HBx: Hepatitis B virus-encoded X protein; HDAC: Histone deacetylase; IKK: IκB
kinase; KSHV: Kaposi’s sarcoma-associated herpesvirus; LMB: Leptomycin B;
LPS: Lipopolysarccharide; MEF: Mouse embryonic fibroblast; NES: Nuclear
export signal; NF-κB: Nuclear factor kappa B; NIK: NF-κB-inducing kinase;
NLS: Nuclear localization sequence; PIAS1: Protein inhibitor of activated
STAT1; pRB: Retinoblastoma tumor suppressor protein; ROS: Reactive oxygen
species; TLR: Toll-like receptor; TNF-α: Tumor-necrosis factor alpha.
Competing interests
These authors declare no competing conflict.
Authors’ contributions
WCH designed the concept, collected information, and prepared the
manuscript and figures. WCH and MCH wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We apologize to colleagues whose relevant contributions were not cited
due to space limitation. We thank Dr. Jennifer L. Hsu for editing the
manuscript. This work was supported by grants from the National Science
Council of Taiwan [NSC-97-2320-B-039-033-MY3, NSC-99-3112-B-039-002, and
NSC 101-2320-B-039-049 to W.C.H, and NSC-101-2911-I-002-303 (iRACE) and
NSC-2632-B-001-MY3 to M.C.H.]; the National Health Research Institutes of
Taiwan [NHRI-EX-98-9812BC to W.C.H]; Cancer Center Research of Excellence
[DOH-TD-C-111-005 to M.C.H.]; and the University of Texas MD Anderson
Cancer Center–China Medical University Hospital Sister Institution Fund.Author details
1Center for Molecular Medicine, China Medical University Hospital, Taichung
40447, Taiwan. 2Graduate Institute of Cancer Biology, China Medical
University, No.6 Hsueh-Hsih Road, Taichung 404, Taiwan. 3The Ph.D. program
for Cancer Biology and Drug Discovery, China Medical University, Taichung
404, Taiwan. 4Department of Biotechnology, Asia University, Taichung 413,
Taiwan. 5Department of Molecular and Cellular Oncology, The University of
Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Blvd, Houston,
Texas 77030, USA.
Received: 16 October 2012 Accepted: 11 January 2013
Published: 23 January 2013References
1. Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives.
Oncogene 2006, 25(51):6680–6684.
2. Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. Cell 2008,
132(3):344–362.
3. Hu MC, Hung MC: Role of IkappaB kinase in tumorigenesis. Future Oncol
2005, 1(1):67–78.
4. Yang JY, Hung MC: A new fork for clinical application: targeting forkhead
transcription factors in cancer. Clin Cancer Res 2009, 15(3):752–757.
5. Solt LA, May MJ: The IkappaB kinase complex: master regulator of NF-
kappaB signaling. Immunol Res 2008, 42(1–3):3–18.
6. Liu F, Xia Y, Parker AS, Verma IM: IKK biology. Immunol Rev 2012,
246(1):239–253.
7. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL,
Goeddel DV: Embryonic lethality, liver degeneration, and impaired NF-
kappa B activation in IKK-beta-deficient mice. Immunity 1999, 10(4):421–429.
8. Sil AK, Maeda S, Sano Y, Roop DR, Karin M: IkappaB kinase-alpha acts in
the epidermis to control skeletal and craniofacial morphogenesis. Nature
2004, 428(6983):660–664.
9. Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S, Gaynor RB:
Regulation of beta-catenin function by the IkappaB kinases. J Biol Chem
2001, 276(45):42276–42286.
10. Olivotto E, Borzi RM, Vitellozzi R, Pagani S, Facchini A, Battistelli M, Penzo M,
Li X, Flamigni F, Li J, Falcieri E, Marcu KB: Differential requirements for
IKKalpha and IKKbeta in the differentiation of primary human
osteoarthritic chondrocytes. Arthritis Rheum 2008, 58(1):227–239.
11. Lee DF, Hung MC: Advances in targeting IKK and IKK-related kinases for
cancer therapy. Clin Cancer Res 2008, 14(18):5656–5662.
12. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS: A
nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent
gene expression. Nature 2003, 423(6940):659–663.
13. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA: Signaling
molecules of the NF-kappa B pathway shuttle constitutively between
cytoplasm and nucleus. J Biol Chem 2002, 277(13):10842–10851.
14. Huang WC, Chen WS, Chen YJ, Wang LY, Hsu SC, Chen CC, Hung MC:
Hepatitis B virus X protein induces IKKalpha nuclear translocation via
Akt-dependent phosphorylation to promote the motility of
hepatocarcinoma cells. J Cell Physiol 2012, 227(4):1446–1454.
15. Huang WC, Ju TK, Hung MC, Chen CC: Phosphorylation of CBP by
IKKalpha promotes cell growth by switching the binding preference of
CBP from p53 to NF-kappaB. Mol Cell 2007, 26(1):75–87.
16. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB: Histone H3
phosphorylation by IKK-alpha is critical for cytokine-induced gene
expression. Nature 2003, 423(6940):655–659.
17. Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A,
Aytes A, Real FX, Capella G, Mayo MW, Espinosa L, Bigas A: Nuclear IKK
activity leads to dysregulated notch-dependent gene expression in
colorectal cancer. Proc Natl Acad Sci USA 2007, 104(1):276–281.
18. Hoberg JE, Yeung F, Mayo MW: SMRT derepression by the IkappaB kinase
alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell
2004, 16(2):245–255.
19. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB: Formation of an
IKKalpha-dependent transcription complex is required for estrogen
receptor-mediated gene activation. Mol Cell 2005, 18(1):71–82.
20. Tu Z, Prajapati S, Park KJ, Kelly NJ, Yamamoto Y, Gaynor RB: IKK alpha
regulates estrogen-induced cell cycle progression by modulating E2F1
expression. J Biol Chem 2006, 281(10):6699–6706.
Huang and Hung Journal of Biomedical Science 2013, 20:3 Page 12 of 13
http://www.jbiomedsci.com/content/20/1/321. Shiah HS, Gao W, Baker DC, Cheng YC: Inhibition of cell growth and
nuclear factor-kappaB activity in pancreatic cancer cell lines by a
tylophorine analogue, DCB-3503. Mol Cancer Ther 2006, 5(10):2484–2493.
22. Hirata Y, Maeda S, Ohmae T, Shibata W, Yanai A, Ogura K, Yoshida H,
Kawabe T, Omata M: Helicobacter pylori induces IkappaB kinase alpha
nuclear translocation and chemokine production in gastric epithelial
cells. Infect Immun 2006, 74(3):1452–1461.
23. Furuya K, Ozaki T, Hanamoto T, Hosoda M, Hayashi S, Barker PA, Takano K,
Matsumoto M, Nakagawara A: Stabilization of p73 by nuclear IkappaB
kinase-alpha mediates cisplatin-induced apoptosis. J Biol Chem 2007,
282(25):18365–18378.
24. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA,
Karin M: Nuclear cytokine-activated IKKalpha controls prostate cancer
metastasis by repressing Maspin. Nature 2007, 446(7136):690–694.
25. Jiang X, Takahashi N, Ando K, Otsuka T, Tetsuka T, Okamoto T: NF-kappa B
p65 transactivation domain is involved in the NF-kappa B-inducing
kinase pathway. Biochem Biophys Res Commun 2003, 301(2):583–590.
26. Matta H, Punj V, Schamus S, Mazzacurati L, Chen AM, Song R, Yang T,
Chaudhary PM: A nuclear role for Kaposi's sarcoma-associated
herpesvirus-encoded K13 protein in gene regulation. Oncogene 2008,
27(39):5243–5253.
27. Temmerman ST, Ma CA, Zhao Y, Keenan J, Aksentijevich I, Fessler M, Brown
MR, Knutsen A, Shapiro R, Jain A: Defective nuclear IKKalpha function in
patients with ectodermal dysplasia with immune deficiency. J Clin Invest
2012, 122(1):315–326.
28. Ear T, Cloutier A, McDonald PP: Constitutive nuclear expression of the I
kappa B kinase complex and its activation in human neutrophils.
J Immunol 2005, 175(3):1834–1842.
29. Ear T, Fortin CF, Simard FA, McDonald PP: Constitutive association of TGF-
beta-activated kinase 1 with the IkappaB kinase complex in the nucleus
and cytoplasm of human neutrophils and its impact on downstream
processes. J Immunol 2010, 184(7):3897–3906.
30. Gloire G, Horion J, El MN, Bex F, Chariot A, Dejardin E, Piette J: Promoter-
dependent effect of IKKalpha on NF-kappaB/p65 DNA binding.
J Biol Chem 2007, 282(29):21308–21318.
31. Schmitz ML, Baeuerle PA: The p65 subunit is responsible for the strong
transcription activating potential of NF-kappa B. EMBO J 1991,
10(12):3805–3817.
32. Park GY, Wang X, Hu N, Pedchenko TV, Blackwell TS, Christman JW: NIK is
involved in nucleosomal regulation by enhancing histone H3
phosphorylation by IKKalpha. J Biol Chem 2006, 281(27):18684–18690.
33. Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional
bridges and scaffolds. J Cell Sci 2001, 114(Pt 13):2363–2373.
34. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA,
Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates
transcriptional activation and AP-1 inhibition by nuclear receptors. Cell
1996, 85(3):403–414.
35. Verma UN, Yamamoto Y, Prajapati S, Gaynor RB: Nuclear role of I kappa B
Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-
kappa B-dependent gene expression. J Biol Chem 2004, 279(5):3509–3515.
36. Chen L, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-kappaB
action regulated by reversible acetylation. Science 2001, 293(5535):
1653–1657.
37. Chen LF, Mu Y, Greene WC: Acetylation of RelA at discrete sites regulates
distinct nuclear functions of NF-kappaB. EMBO J 2002, 21(23):6539–6548.
38. Ashburner BP, Westerheide SD, Baldwin AS Jr: The p65 (RelA) subunit of
NF-kappaB interacts with the histone deacetylase (HDAC) corepressors
HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol
2001, 21(20):7065–7077.
39. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW:
Modulation of NF-kappaB-dependent transcription and cell survival by
the SIRT1 deacetylase. EMBO J 2004, 23(12):2369–2380.
40. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W,
Verdin E: Enzymatic activity associated with class II HDACs is dependent
on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell
2002, 9(1):45–57.
41. Hoberg JE, Popko AE, Ramsey CS, Mayo MW: IkappaB kinase alpha-
mediated derepression of SMRT potentiates acetylation of RelA/p65 by
p300. Mol Cell Biol 2006, 26(2):457–471.
42. Yang SR, Valvo S, Yao H, Kode A, Rajendrasozhan S, Edirisinghe I, Caito S,
Adenuga D, Henry R, Fromm G, Maggirwar S, Li JD, Bulger M, Rahman I: IKKalpha causes chromatin modification on pro-inflammatory genes by
cigarette smoke in mouse lung. Am J Respir Cell Mol Biol 2008,
38(6):689–698.
43. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M: IKKalpha limits
macrophage NF-kappaB activation and contributes to the resolution of
inflammation. Nature 2005, 434(7037):1138–1143.
44. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, Yang R, Mink S, Shultz
D, Bellone CJ, Loo JA, Shuai K: Proinflammatory stimuli induce IKKalpha-
mediated phosphorylation of PIAS1 to restrict inflammation and
immunity. Cell 2007, 129(5):903–914.
45. Anest V, Cogswell PC, Baldwin AS Jr: IkappaB kinase alpha and p65/RelA
contribute to optimal epidermal growth factor-induced c-fos gene
expression independent of IkappaBalpha degradation. J Biol Chem 2004,
279(30):31183–31189.
46. Dong W, Li Y, Gao M, Hu M, Li X, Mai S, Guo N, Yuan S, Song L: IKKalpha
contributes to UVB-induced VEGF expression by regulating AP-1
transactivation. Nucleic Acids Res 2012, 40(7):2940–2955.
47. Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM,
Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, Dhar D, Karin M, Chen CH,
Hung MC: IKKalpha activation of NOTCH links tumorigenesis via FOXA2
suppression. Mol Cell 2012, 45(2):171–184.
48. Andersen P, Uosaki H, Shenje LT, Kwon C: Non-canonical Notch signaling:
emerging role and mechanism. Trends Cell Biol 2012, 22(5):257–265.
49. Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW:
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator
activity by I kappa B kinase. Mol Cell Biol 2002, 22(10):3549–3561.
50. Bubici C, Papa S, Dean K, Franzoso G: Mutual cross-talk between reactive
oxygen species and nuclear factor-kappa B: molecular basis and
biological significance. Oncogene 2006, 25(51):6731–6748.
51. Fan C, Li Q, Ross D, Engelhardt JF: Tyrosine phosphorylation of I kappa B
alpha activates NF kappa B through a redox-regulated and c-Src-
dependent mechanism following hypoxia/reoxygenation. J Biol Chem
2003, 278(3):2072–2080.
52. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C,
Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF: Tyrosine
phosphorylation of I kappa B-alpha activates NF-kappa B without
proteolytic degradation of I kappa B-alpha. Cell 1996, 86(5):787–798.
53. Yamaguchi T, Miki Y, Yoshida K: Protein kinase C delta activates IkappaB-
kinase alpha to induce the p53 tumor suppressor in response to
oxidative stress. Cell Signal 2007, 19(10):2088–2097.
54. Yamaguchi T, Kimura J, Miki Y, Yoshida K: The deubiquitinating enzyme
USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling
pathway in response to tumor necrosis factor alpha (TNFalpha). J Biol
Chem 2007, 282(47):33943–33948.
55. Yoshida K, Ozaki T, Furuya K, Nakanishi M, Kikuchi H, Yamamoto H, Ono S,
Koda T, Omura K, Nakagawara A: ATM-dependent nuclear accumulation of
IKK-alpha plays an important role in the regulation of p73-mediated
apoptosis in response to cisplatin. Oncogene 2008, 27(8):1183–1188.
56. Baldwin AS Jr, Azizkhan JC, Jensen DE, Beg AA, Coodly LR: Induction of NF-
kappa B DNA-binding activity during the G0-to-G1 transition in mouse
fibroblasts. Mol Cell Biol 1991, 11(10):4943–4951.
57. Cressman DE, Greenbaum LE, Haber BA, Taub R: Rapid activation of post-
hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary
response in the regenerating liver. J Biol Chem 1994, 269(48):30429–30435.
58. Biswas DK, Cruz AP, Gansberger E, Pardee AB: Epidermal growth factor-
induced nuclear factor kappa B activation: A major pathway of cell-cycle
progression in estrogen-receptor negative breast cancer cells. Proc Natl
Acad Sci USA 2000, 97(15):8542–8547.
59. Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W, Schmitz ML: Repression
of NF-kappaB impairs HeLa cell proliferation by functional interference
with cell cycle checkpoint regulators. Oncogene 1999, 18(21):3213–3225.
60. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent
kinases. Genes Dev 1995, 9(10):1149–1163.
61. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995,
81(3):323–330.
62. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr: NF-kappaB
controls cell growth and differentiation through transcriptional
regulation of cyclin D1. Mol Cell Biol 1999, 19(8):5785–5799.
63. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M: NF-
kappaB function in growth control: regulation of cyclin D1 expression
and G0/G1-to-S-phase transition. Mol Cell Biol 1999, 19(4):2690–2698.
Huang and Hung Journal of Biomedical Science 2013, 20:3 Page 13 of 13
http://www.jbiomedsci.com/content/20/1/364. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee
RJ, Segall JE, Westwick JK, Der CJ, Pestell RG: Integration of Rac-dependent
regulation of cyclin D1 transcription through a nuclear factor-kappaB-
dependent pathway. J Biol Chem 1999, 274(36):25245–25249.
65. Bash J, Zong WX, Gelinas C: c-Rel arrests the proliferation of HeLa cells
and affects critical regulators of the G1/S-phase transition. Mol Cell Biol
1997, 17(11):6526–6536.
66. Sheehy AM, Schlissel MS: Overexpression of RelA causes G1 arrest and
apoptosis in a pro-B cell line. J Biol Chem 1999, 274(13):8708–8716.
67. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin
M: Abnormal morphogenesis but intact IKK activation in mice lacking
the IKKalpha subunit of IkappaB kinase. Science 1999, 284(5412):316–320.
68. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H,
Yoshikawa K, Terada N, Akira S: Limb and skin abnormalities in mice
lacking IKKalpha. Science 1999, 284(5412):313–316.
69. Chen F, Castranova V, Shi X: New insights into the role of nuclear factor-
kappaB in cell growth regulation. Am J Pathol 2001, 159(2):387–397.
70. Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M: IKKalpha controls formation of
the epidermis independently of NF-kappaB. Nature 2001, 410(6829):710–714.
71. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN: IkappaB kinase
alpha regulates subcellular distribution and turnover of cyclin D1 by
phosphorylation. J Biol Chem 2005, 280(40):33945–33952.
72. Marinari B, Moretti F, Botti E, Giustizieri ML, Descargues P, Giunta A, Stolfi C,
Ballaro C, Papoutsaki M, Alema S, Monteleone G, Chimenti S, Karin M,
Costanzo A: The tumor suppressor activity of IKKalpha in stratified
epithelia is exerted in part via the TGF-beta antiproliferative pathway.
Proc Natl Acad Sci USA 2008, 105(44):17091–17096.
73. Brandl M, Seidler B, Haller F, Adamski J, Schmid RM, Saur D, Schneider G:
IKK(alpha) controls canonical TGF(ss)-SMAD signaling to regulate genes
expressing SNAIL and SLUG during EMT in panc1 cells. J Cell Sci 2010,
123(Pt 24):4231–4239.
74. Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, Verma IM:
IKK1-deficient mice exhibit abnormal development of skin and skeleton.
Genes Dev 1999, 13(10):1322–1328.
75. Schmidt-Ullrich R, Aebischer T, Hulsken J, Birchmeier W, Klemm U,
Scheidereit C: Requirement of NF-kappaB/Rel for the development of
hair follicles and other epidermal appendices. Development 2001,
128(19):3843–3853.
76. Martin GR: The roles of FGFs in the early development of vertebrate
limbs. Genes Dev 1998, 12(11):1571–1586.
77. Kufer TA, Nigg EA, Sillje HH: Regulation of Aurora-A kinase on the mitotic
spindle. Chromosoma 2003, 112(4):159–163.
78. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X:
Mitotic requirement for aurora A kinase is bypassed in the absence of
aurora B kinase. FEBS Lett 2005, 579(16):3385–3391.
79. Prajapati S, Tu Z, Yamamoto Y, Gaynor RB: IKKalpha regulates the mitotic
phase of the cell cycle by modulating Aurora A phosphorylation. Cell
Cycle 2006, 5(20):2371–2380.
80. Zhu F, Xia XJ, Liu BG, Shen JJ, Hu YH, Person M, Hu YL: IKK alpha shields
14-3-3 sigma, a G(2)/M cell cycle checkpoint gene, from
hypermethylation, preventing its silencing. Mol Cell 2007, 27(2):214–227.
81. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M: B-cell-derived
lymphotoxin promotes castration-resistant prostate cancer. Nature 2010,
464(7286):302–305.
82. Chen T, Wang LH, Farrar WL: Interleukin 6 activates androgen receptor-
mediated gene expression through a signal transducer and activator of
transcription 3-dependent pathway in LNCaP prostate cancer cells.
Cancer Res 2000, 60(8):2132–2135.
83. Hu W, Jans DA: Efficiency of importin alpha/beta-mediated nuclear
localization sequence recognition and nuclear import. Differential role of
NTF2. J Biol Chem 1999, 274(22):15820–15827.
84. Truant R, Kang Y, Cullen BR: The human tap nuclear RNA export factor
contains a novel transportin-dependent nuclear localization signal that
lacks nuclear export signal function. J Biol Chem 1999, 274(45):32167–32171.
85. Quimby BB, Dasso M: The small GTPase Ran: interpreting the signs. Curr
Opin Cell Biol 2003, 15(3):338–344.
86. Charu Kanwal HL, Carol S, Lim: Model system to study classical nuclear
export signals. AAPS PharmSci 2002, 4(3):1–8.
87. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB
activation by tumour necrosis factor requires the Akt serine-threonine
kinase. Nature 1999, 401(6748):82–85.88. Starkey JM, Haidacher SJ, LeJeune WS, Zhang X, Tieu BC, Choudhary S,
Brasier AR, Denner LA, Tilton RG: Diabetes-induced activation of canonical
and noncanonical nuclear factor-kappaB pathways in renal cortex.
Diabetes 2006, 55(5):1252–1259.
89. Lubin FD, Sweatt JD: The IkappaB kinase regulates chromatin structure
during reconsolidation of conditioned fear memories. Neuron 2007,
55(6):942–957.
90. Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure
trove for drug development. Nat Rev Drug Discov 2004, 3(1):17–26.
91. Niederberger E, Geisslinger G: The IKK-NF-kappaB pathway: a source for novel
molecular drug targets in pain therapy? FASEB J 2008, 22(10):3432–3442.
92. Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? hopes
and pitfalls. Nat Rev Drug Discov 2009, 8(1):33–40.
doi:10.1186/1423-0127-20-3
Cite this article as: Huang and Hung: Beyond NF-κB activation: nuclear
functions of IκB kinase α. Journal of Biomedical Science 2013 20:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
